Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Biologic Lung Volume Reduction · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single | EXPERIMENTAL | all patients are treated with the experimental therapy |
| Name | Type | Description |
|---|---|---|
| Biologic Lung Volume Reduction | BIOLOGICAL | 20 mL Hydrogel |
Inclusion Criteria: * clinical diagnosis of advanced homogeneous or upper lobe predominant emphysema demonstrated by CT scan * age \>/= 40 years * clinically significant dyspnea * failure of standard medical therapy (typically inhaled beta agonist \& inhaled anticholinergic) to relieve symptoms * p...
Biologic Lung Volume Reduction is an investigational therapy being studied for the treatment of homogeneous emphysema, a form of chronic obstructive pulmonary disease. It is designed to reduce lung volume in patients with this condition. The drug is currently in clinical development and has not been approved by regulatory authorities.
Biologic Lung Volume Reduction is being developed by cbdMD, Inc., a company traded on the stock market under the ticker symbol YCBD. The company is conducting clinical research on this therapy for homogeneous emphysema. As of the latest available information, the drug is in Phase 2 clinical development.
Biologic Lung Volume Reduction is in Phase 2 clinical development. It has completed one Phase 2 clinical trial for homogeneous emphysema. The drug is still investigational and has not received regulatory approval. Further clinical studies may be needed to evaluate its safety and efficacy.
Biologic Lung Volume Reduction has been studied in one completed clinical trial with the identifier NCT00630227. This Phase 2 study, titled 'Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study,' enrolled 33 participants with homogeneous emphysema in the United States. The trial was uncontrolled and did not use randomization or blinding.
Biologic Lung Volume Reduction is a monoclonal antibody designed to target and reduce lung volume in patients with homogeneous emphysema. By binding to specific molecular targets, it aims to modify the lung tissue to improve respiratory function. The exact mechanism of action is part of its investigational profile.
Biologic Lung Volume Reduction is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for homogeneous emphysema. The completed clinical trial NCT00630227 has provided initial data, but the therapy has not yet received regulatory approval for commercial use.